The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Prior treatment with BsAb does not impair response to CAR-T in patients with large B-cell lymphoma
Gloria Iacoboni, MD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, gives an overview of a retrospective, international study looking at outcomes in patients with large B-cell lymphoma (LBCL) who were treated with CAR T-cell therapy following previous bispecific antibody (BsAb) treatment. The study showed that previous exposure to BsAb treatment did not negatively impact the survival outcomes of patients receiving CAR-T, and a lack of response to BsAb treatment did not lead to impaired response after CAR T-cell infusion. Dr Iacaboni does emphasize some limitations of the study, which should be addressed in future cohorts. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: AstraZeneca, MSD, Gilead Sciences, Celgene/Bristol-Myers Squibb, Novartis, Janssen, Miltenyi, AbbVie
Consultancy: Gilead Sciences, Celgene/Bristol-Myers Squibb, Novartis, Autolus, Miltenyi
